Liting Wang
Impact in
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
- Biomedical Engineering top 5%
- Nanoplatforms for cancer theranostics
Papers in
- Biomaterials 13
- Nanoparticle-Based Drug Delivery 13
-
- Nanoplatforms for cancer theranostics 9
- Co-authors
- Yourong Duan (19 shared papers)Hiroaki Kasai (1 shared paper)Fwu‐Ling Lee (1 shared paper)Qianqian Guo (6 shared papers)Chuanrong Chen (10 shared papers)Zhihua Wu (10 shared papers)Jiali Zhang (8 shared papers)Bolin Chen (2 shared papers)
- Journals
- Advances in Therapy (5 papers)Biomaterials (5 papers)PLoS ONE (4 papers)Advanced Science (4 papers)Advanced Healthcare Materials (3 papers)
- Partner nations
- ChinaTaiwanUnited States
In The Last Decade
Liting Wang
145 papers receiving 2.9k citations
Liting Wang's Hit Papers
Peers
Comparison fields: 5 of 140
- Biomaterials 277
- Biomedical Engineering 414
- Drug Discovery 3
- Clinical Biochemistry 43
- Molecular Biology 559
Countries citing papers authored by Liting Wang
This map shows the geographic impact of Liting Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liting Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liting Wang more than expected).
Fields of papers citing papers by Liting Wang
This network shows the impact of papers produced by Liting Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liting Wang. The network helps show where Liting Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Liting Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 155 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 264 | |
| 2 | 2022 | 184 | |
| 3 | 2013 | 102 | |
| 4 | 2022 | 94 | |
| 5 | 2023 | 90 | |
| 6 | 2019 | 84 | |
| 7 | 2014 | 77 | |
| 8 | 2020 | 68 | |
| 9 | 2021 | 68 | |
| 10 | 2010 | 61 | |
| 11 | 2018 | 61 | |
| 12 | 2013 | 59 | |
| 13 | 2016 | 58 | |
| 14 | 2019 | 50 | |
| 15 | 2022 | 50 | |
| 16 | Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial Hit paper breakdown → | 2025 | 46 |
| 17 | 2021 | 45 | |
| 18 | 2016 | 42 | |
| 19 | 2019 | 41 | |
| 20 | 2023 | 39 |
About Liting Wang
Liting Wang is a scholar working on Biomaterials, Biomedical Engineering, Economics and Econometrics, Molecular Biology and Epidemiology, having authored 155 papers that have together received 3k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (14 papers), Nanoparticle-Based Drug Delivery (13 papers), Nanoplatforms for cancer theranostics (9 papers), Autophagy in Disease and Therapy (6 papers), Extracellular vesicles in disease (5 papers), Ferroptosis and cancer prognosis (4 papers), Acute Kidney Injury Research (3 papers) and Plant Stress Responses and Tolerance (3 papers). The work is most often cited by research in Biomaterials (277 citations), Biomedical Engineering (414 citations), Drug Discovery (3 citations), Clinical Biochemistry (43 citations) and Molecular Biology (559 citations). Liting Wang has collaborated with scholars based in China, Taiwan and United States. Frequent co-authors include Yourong Duan, Hiroaki Kasai, Fwu‐Ling Lee, Qianqian Guo, Chuanrong Chen, Zhihua Wu, Jiali Zhang, Bolin Chen, Shing‐Hwa Liu and Kuo‐How Huang. Their work appears in journals such as Advances in Therapy, Biomaterials, PLoS ONE, Advanced Science and Advanced Healthcare Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.